Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avax

Executive Summary

FDA questions whether M-Vax and O-Vax "are sufficiently developed for ongoing clinical trials to be considered adequate to support a BLA," Avax reports. The autologous cancer vaccines were put on clinical hold in March, at which time Avax maintained that the hold was not related to manufacturing issues (1"The Pink Sheet" April 2, In Brief). Written communication from FDA indicates that the hold is related to Avax' handling of tumor cells, preparation of vaccines and manufacturing practices. An investigation of the firm's Philadelphia manufacturing facility is underway. Exec VP-R&D Ernest Yankee, PhD, and VP-Operations Kamy Behzadi, PhD, resigned at the request of the board of directors

You may also be interested in...



Avax M-Vax and O-Vax

Clinical activities for its M-Vax and O-Vax autologous cancer vaccines have been placed on clinical hold pending further FDA review, company announces. "The FDA is currently examining the need to establish the sterility of tumor cells received by the company to prepare individualized cancer vaccines," Avax said. Firm maintains hold is not related to any concern with manufacturing, but is part of FDA's "evolving requirements for cell-derived products"

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel